ACMI and NSWC Indian head break ground on $250 million Maryland Energetics Innovation Hub for defense manufacturing


The American Center for Manufacturing & Innovation has broken ground on the Maryland Energetics Innovation Hub near Naval Surface Warfare Center Indian Head Division. The hub is intended to modernize how the United States develops, tests and scales critical technologies and energetics production for the military.

The project is backed by an initial $50 million award from NSWC Indian Head Division. ACMI said the hub is expected to catalyze more than $200 million in additional private investment.

The Maryland Energetics Innovation Hub will include multiple new state-of-the-art buildings outside the gates of NSWC Indian Head Division. The site will host companies and research institutions working on U.S. military priorities.

The hub will focus on eight priority innovation areas. These include energetics for uncrewed systems, next-generation propulsion systems, manufacturing automation and other capabilities needed to strengthen the U.S. munitions industrial base.

 

“This is a generational investment. ACMI is helping America become faster at moving from ideas to production – faster to innovate, faster to manufacture, and faster to scale the technologies that strengthen our national defense,” said John Burer, Founder and CEO of ACMI.

“MEIH brings together the infrastructure, capital, and private-sector talent needed to rapidly advance new producers and technologies. By leading the effort to recruit and convene top defense technology companies around NSWC Indian Head Division’s priority mission areas, ACMI is creating a new kind of industrial ecosystem designed to accelerate collaboration, compress timelines, and turn breakthrough innovation into operational capability at unprecedented speed,” Burer said.

ACMI also announced that Energetics Technology Center and Applied Research Associates will serve as inaugural tenants and partners. The organization said it is in active talks with several leading defense technology companies about expanding to the hub.

The groundbreaking ceremony brought together military leaders, elected officials, industry executives, academic partners and manufacturing stakeholders. Participants included representatives from the Johns Hopkins Applied Physics Laboratory, National Nuclear Security Administration, National Defense Industrial Association, Parsons, Leidos and Rafael-USA.

“This initiative ensures that NSWC Indian Head Division remains at the forefront of energetics innovation, scale-up, and production,” said Captain Steve Duba, NSWC IHD Commanding Officer.

“By bringing together government and industry partners in a collaborative environment, we can accelerate the development and fielding of critical capabilities that strengthen the Navy’s Arsenal and the larger munitions industrial base,” Duba said.

“Southern Maryland has long been a cornerstone of the nation’s energetics enterprise, and the Maryland Energetics Innovation Hub builds on that strong foundation,” said William Durant, CEO and President of ETC.

“ETC is excited to work alongside ACMI and NSWC Indian Head Division to advance critical technologies and support the next generation of capabilities for the nation’s warfighters,” Durant said.

“Local manufacturing is critical to our economy and our workforce. The new Maryland Energetics Innovation Hub is an important investment in supporting local manufacturing and will further cement our state’s leadership in this critical space,” said U.S. Senator Chris Van Hollen.

“This trailblazing facility will help strengthen our national security, create good-paying jobs, and drive economic growth here in Indian Head,” Van Hollen said.

“Today’s groundbreaking for the Maryland Energetic Innovation Hub marks a crucial and exciting step in supporting Indian Head’s mission, expanding off base partnerships, and improving our nation’s military readiness,” said U.S. Representative Sarah Elfreth.

“The Naval Surface Warfare Center at Indian Head is already at the cutting-edge of energetics research for the Department of Defense. This new partnership will only broaden their horizons and solidify Maryland’s role at the forefront of innovation in this ever-evolving global arena,” Elfreth said.

“I’m grateful to see funding and partnerships like these that not only bolster our national security, but invest in our communities,” Elfreth added.

“The Western Charles County Technology Corridor continues to strengthen its position as a competitive hub for defense, energetics, and advanced technology industries,” said Jim Chandler, Director of the Charles County Economic Development Department.

“We are seeing growth in partnerships, investment, and innovation that are expanding opportunities for both new and existing businesses while reinforcing Charles County’s long-term economic competitiveness. The groundbreaking of the Maryland Energetics Innovation Hub marks an important milestone,” Chandler said.

 

The Maryland investment builds on ACMI’s regional manufacturing campus model. ACMI said the model is designed to revitalize U.S. manufacturing capacity through shared infrastructure, advanced production ecosystems and public-private partnerships.

Earlier this year, ACMI broke ground on its 1,100-acre National Security Industrial Hub in Indiana. That defense manufacturing campus is backed by an initial $75 million award from the Department of War.

ACMI said the Maryland and Indiana hubs together represent more than $1 billion in investment in the defense industrial base. Initial operations at the Maryland Energetics Innovation Hub are expected to begin in 2027 as phased construction advances.

The hub is expected to create high-quality jobs, attract additional private investment and support the growth of domestic manufacturing capabilities critical to national security. ACMI said it will also help accelerate defense manufacturing modernization and expand domestic energetics capacity.

ACMI is an industrial group focused on revitalizing the U.S. manufacturing base by building infrastructure and supporting manufacturers as they scale. NSWC Indian Head Division is a Naval Sea Systems Command field activity focused on ordnance, energetics and explosive ordnance disposal solutions.

Free Training

Source link

Samsung Biologics looks to scale up U.S. manufacturing in Maryland



Samsung Biologics CEO John Rim delivers his keynote speech outlining the company's future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

 
SAN FRANCISCO — Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production amid shifting trade policies.
 
“The GSK facility acquisition is anticipated to close in March this year, giving us regional presentation in the United States,” said CEO John Rim at the 44th J.P. Morgan Health Care Conference on Tuesday. “It will have flexibility to take on additional products beyond the GSK product line.”
 
Samsung Biologics announced in December 2025 that it would acquire the Rockville facility from GlaxoSmithKline for $280 million. The plant has an annual production capacity of 60,000 liters (15,850 gallons).
 
 
“It [the U.S. factory] has always been a higher cost area and everybody knows that, but for us, the U.S. was critical and the reason for that is we’ve lost customers because we didn’t have a U.S. presence,” Rim said, adding that clients wanted supply chain resiliency.
 
While the Rockville facility is modest in scale compared to Samsung Biologics’ five plants in Songdo, Korea — which together have a combined capacity of 785,000 liters — the company said the U.S. site can be expanded by an additional 20,000 to 40,000 liters.
 
“Everybody understands that there’s some pricing flexibility, so we’ll have to work through,” Rim said. “But we do see that having the Rockfield facility will open up new venues of growth for us.”
 
Initially, the plant will continue manufacturing existing GSK products, including Benlysta, a monoclonal antibody treatment for lupus. Over time, the facility is expected to be upgraded to support multiple modalities, particularly antibody production.
 
Samsung Biologics CEO John Rim delivers his keynote speech outlining the company's future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

 
“Whether antibody drug conjugate [ADC] capabilities are added in the future will depend on demand,” Rim added at a separate press conference held with the Korean press on Monday.
 
With the facility, the Korean company will have more than 500 employees working at the site, and plans to recruit more U.S talent in the future.
 
The company’s main production site, however, remains rooted in its Songdo campus as U.S. tariffs on biopharmaceutical imports have largely dissolved. While tariffs were previously discussed at levels as high as 250 percent, subsequent bilateral negotiations have capped potential tariffs at 15 percent, significantly reducing trade-related risk.
 
In parallel, Samsung Biologics is continuing to expand domestically. Construction of a sixth plant is expected to begin between 2026 and 2027, and the company has secured land for a third phase of its Songdo manufacturing campus. It plans to invest approximately 7 trillion won ($4.7 billion) through 2034 to build additional production facilities.
 
Looking ahead, Rim said the company’s investment strategy, including mergers and acquisitions, will remain focused on antibody manufacturing.
 
 
The global biopharmaceutical market is projected to grow at a compound annual growth rate of 10 percent, from $565 billion in 2025 to $921 billion in 2030, according to market researcher Evaluate Pharma, driven in particular by monoclonal antibodies, multispecific antibodies, ADCs and fusion proteins.
 
“The antibody market is so large that even single-digit growth translates into meaningful demand,” Rim said. “Other segments may grow faster in percentage terms, but their overall impact is limited by smaller market size.”
 
Samsung Biologics is also closely monitoring developments in GLP-1 therapies — particularly the shift toward oral formulations — as well as opportunities in peptide manufacturing.
 
The company has rebranded its contract manufacturing offering under the name ExcellenS, a move that reflects its emphasis on tailored production and operational efficiency, based on standardized and scalable manufacturing processes.
 
Samsung Biologics is scheduled to report its fourth-quarter and full-year 2025 earnings on Jan. 21. The company recorded a record annual order intake of 6.8 trillion won in 2025, with cumulative orders surpassing $21 billion.
 

BY LEE JAE-LIM [[email protected]]

Free Training

Source link

Samsung Biologics to establish first U.S. manufacturing base in Maryland


ROCKVILLE, MD—In a major win for Maryland’s life sciences sector, Governor Wes Moore announced this week that South Korea-based Samsung Biologics will open its first United States manufacturing facility in Rockville. The move follows a strategic international trade mission led by the Governor earlier this year to strengthen economic ties with East Asian tech leaders.

Samsung Biologics, the world’s largest contract drug manufacturer, has reached an agreement to acquire a manufacturing campus in Rockville from GSK for $280 million. The facility will serve as a cornerstone for the company’s expansion into the American market, providing a localized hub for the production of critical biologic medicines.

Strengthening the Global Supply Chain

The acquisition secures a site that currently houses two high-standard manufacturing plants with a combined capacity of 60,000 liters. Samsung Biologics plans to not only maintain the current production of existing medicines but also invest in significant technology upgrades and capacity expansions.

By establishing a footprint in Maryland, the company aims to create a more resilient supply chain for life-saving therapeutics, offering clinical and commercial production capabilities on U.S. soil.

Economic Impact and Job Retention

A primary component of the agreement is the preservation of Maryland’s specialized workforce. Samsung Biologics has committed to:

  • Retaining more than 500 existing jobs at the Rockville site.
  • Creating additional high-skilled positions as production capacity grows.
  • Generating new opportunities for local Maryland suppliers.

Governor Moore noted that the deal is a testament to the state’s highly skilled workforce and its status as a premier global bio-cluster. The announcement builds on a record year for Maryland’s biopharmaceutical industry, which recently saw a $2 billion investment from AstraZeneca and the arrival of several other international firms.

Strategic Location in the I-270 Tech Corridor

Montgomery County officials emphasized that Rockville’s proximity to federal institutions like the FDA and the NIH makes it an ideal location for global companies navigating complex regulatory environments. County Executive Marc Elrich described the investment as a robust endorsement of the local ecosystem, which relies on a combination of talent, diversity, and public-private partnerships.

The transition is expected to be finalized following the formal close of the acquisition, with Samsung Biologics integrating the Rockville campus into its global network that already spans five major plants in South Korea.

Please follow and like us:

fb-share-icon
Tweet


Chris Montcalmo - Baltimore Acoustic Musician


Free Training

Source link